TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15111342
Drug: Infusional 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusional 5-FU 200 mg/m² daily continuous infusion for 18 weeks with epirubicin 60 mg/m² and cisplatin 60 mg/m² (infusional ECisF)
Study: 15111342
Drug: Conventional bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bolus doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC)
Study: 28254231
Drug: Cervical ripening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical ripening balloon (CRB) group with double‐balloon catheter (COOK CRB), inflated with 30‐80 mL of normal saline for 12 hours
Study: 28254231
Drug: Non-CRB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-CRB group (vaginal and oral misoprostol alone)
Study: 22946635
Drug: Yogurt containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt containing Lactobacillus rhamnosus GG (LGG) and fructooligosaccharide (FOS) Actilight(®) administered daily for 4 weeks
Study: 19258143
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 1% lidocaine
Study: 21658884
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 0.9% NaCl
Study: 19366275
Drug: Ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 10 mg twice daily for 7 days, followed by 15 mg twice daily if no visual symptoms reported
Study: 15823773
Drug: Sibutramine mesylate
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine mesylate hemihydrate (17.3 mg oral dose)
Study: 15823773
Drug: Sibutramine hydrochloride
Normalized name: Sibutramine Hydrochloride
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine hydrochloride monohydrate (15 mg oral dose)
Study: 11700399
Drug: rTFPI at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTFPI at 0.025 mg/kg/hr
Study: 11700399
Drug: rTFPI at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTFPI at 0.05 mg/kg/hr
Study: 11700399
Drug: rTFPI (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTFPI (both doses)
Study: 9404177
Drug: Enflurane administered
Normalized name: Enflurane
DrugBank: Enflurane (DB00228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enflurane administered via a laryngeal mask airway (LMA)
Study: 9404177
Drug: Enflurane anaesthesia
Normalized name: Enflurane
DrugBank: Enflurane (DB00228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enflurane anaesthesia administered using a face mask
Study: 2961307
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of 5'-DFUR (800 mg/m2/day)
Study: 2961307
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of 5'-DFUR (1,400 mg/m2/day for 4 days followed by 3 days off)
Study: 22759198
Drug: Apixaban 0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 0.5-2.5 mg as solution or 5-50 mg as tablets
Study: 24725442
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg
Study: 14719426
Drug: Adenosine 10
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 10 mg in 5 ml saline with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 1)
Study: 14719426
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml saline (placebo control) with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 2)
Study: 8197031
Drug: Hydrocodone bitartrate
Normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hydrocodone bitartrate 7.5 mg with acetaminophen 500 mg
Study: 8197031
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 30 mg with acetaminophen 300 mg
Study: 3147522
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg twice daily for 1 week)
Study: 3147522
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for 1 week)
Study: 28130435
Drug: GnRH-agonist protocol
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-agonist protocol
Study: 31346609
Drug: Ongoing injection
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing injection drug use (IDU)
Study: 31329983
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (PS)
Study: 23354314
Drug: Mild water‐filtered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild water‐filtered near infrared whole body hyperthermia twice a week
Study: 18469732
Drug: Probiotic Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Escherichia coli Nissle 1917 (EcN) suspension (1-3 mL daily for 21 days)
Study: 16556690
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (INH)
Study: 12545256
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Open craniotomy and Stereotactic biopsy)
Study: 8727434
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine infusion (2 micrograms.kg-1.min-1) during 2-hour periods
Study: 8727434
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine infusion (2 micrograms.kg-1.min-1) after 48 hours
Study: 8727434
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine infusion (2 micrograms.kg-1.min-1)
Study: 1888820
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg fluconazole daily for 14‐28 days
Study: 1888820
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg fluconazole weekly for 6 months
Study: 1888820
Drug: Placebo weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo weekly for 6 months
Study: 6384850
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g, 12 doses)
Study: 3532966
Drug: Cyclosporin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (10 mg/kg daily for two months)
Study: 29231607
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of regular acupuncture and contralateral needling technique at distal acupoints
Study: 23550665
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy Japanese version (CST-J), 14 sessions, twice a week for 7 weeks
Study: 23550665
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy Japanese version (CST-J)
Study: 17978857
Drug: Intraoperative single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative single bolus rabbit ATG in a dose of 9 mg/kg
Study: 16857836
Drug: FeSO4 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4 (3 mg vs 20 mg)
Study: 9268948
Drug: MVP (platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVP (platinum-based chemotherapy)
Study: 9268948
Drug: MACC (non-platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACC (non-platinum-based combination chemotherapy)
Study: 8274720
Drug: vitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin therapy
Study: 3544860
Drug: Pulsatile glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulsatile glucagon infusion (812.5 ng X min‐1, 2/11 min on/off)
Study: 3544860
Drug: Continuous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous glucagon infusion (125 ng X min‐1)
Study: 3544860
Drug: Pulsatile glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulsatile glucagon infusion
Study: 28478984
Drug: Walking Bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking Bleaching (WB) technique; sodium perborate and 20% hydrogen peroxide applied in pulp chambers, replaced weekly for 4 weeks
Study: 26677667
Drug: ZHU's Tiaojing
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZHU's Tiaojing Cuyun Recipe (TCR), one dose per day for 2 courses (3 menstrual cycles each).
Study: 26677667
Drug: Clomifene Citrate
Normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomifene Citrate (CC), 50 mg per day for 2 courses (3 menstrual cycles each).
Study: 22384541
Drug: Clomifene Citrate
Normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomifene Citrate (CC)
Study: 22975216
Drug: Peg‐IFN 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN 100 μg SC once weekly for 36 months
Study: 22975216
Drug: IFN 3
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 3 MU SC three times weekly for 18 months
Study: 1385295
Drug: Acyclovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (400 mg twice daily)
Study: 20833591
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg twice daily)
Study: 17139367
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clopidogrel and aspirin
Study: 17139367
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clopidogrel and cilostazol
Study: 17139367
Drug: Triple-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug combination (aspirin, clopidogrel, cilostazol)
Study: 11112089
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with evening meals
Study: 11112089
Drug: Atorvastatin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin after meals
Study: 3084617
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (DPA) 400 mg orally
Study: 16980907
Drug: Carraguard (carrageenan-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carraguard (carrageenan-derived microbicide gel)
Study: 16980907
Drug: Placebo (methylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (methylcellulose gel)
Study: 12738504
Drug: Soy-derived isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-derived isoflavones (72 mg daily)
Study: 9285659
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone (10 mg/kg/day for a minimum of 14 days, followed by 200 mg/day for maintenance)
Study: 9285659
Drug: Conventional antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiarrhythmic drug therapy (sotalol or propafenone)
Study: 9285659
Drug: Conventional antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiarrhythmic drug therapy
Study: 8222496
Drug: L-365,260 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260 50 mg
Study: 8222496
Drug: L-365,260 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260 (all doses combined)
Study: 3534862
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg two times a day) for 8 weeks
Study: 3534862
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg/day) for 8 weeks
Study: 25023977
Drug: Cinnarizine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (1.5 mg/kg/day for children <30 kg or 50 mg for children >30 kg, administered at bedtime)
Study: 18004920
Drug: Maxillary canines
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary canines (treatment group)
Study: 18004920
Drug: Maxillary microscrew
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary microscrew implants (implant group)
Study: 16408384
Drug: Formula supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplemented with 0.4 g/100ml oligosaccharides (9 to 1 mixture of galacto- and fructooligosaccharides)
Study: 9931077
Drug: Nifedipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (all formulations)
Study: 9931077
Drug: Other active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other active drug controls
Study: 9931077
Drug: Immediate-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release nifedipine
Study: 6411792
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding (Vivonex HN) via needle catheter jejunostomy (NCJ) starting at 18 hours postoperatively, advanced to 3,000 cc/day within 72 hours.
Study: 19039085
Drug: Individually adjusted
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually adjusted GH dose (IAD) starting at 0.035 mg/kg per day, increased to 0.067 mg/kg per day if growth prediction was <0.75 at 3 months
Study: 19039085
Drug: Fixed high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed high GH dose (FHD) at 0.067 mg/kg per day throughout the study
Study: 15126234
Drug: SSRI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI group (paroxetine 10 mg-40 mg/day and sertraline 50 mg-150 mg/day)
Study: 9146858
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) 100 mg single oral dose
Study: 3622539
Drug: Nalbuphine (≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (≤ 20 mg)
Study: 3622539
Drug: Diamorphine (≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine (≤ 5 mg)
Study: 25045825
Drug: MF59®-adjuvanted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59®-adjuvanted trivalent influenza vaccine (aTIV)
Study: 25045825
Drug: Non-adjuvanted seasonal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted seasonal influenza vaccine (TIV)
Study: 16396699
Drug: Amtolmetin guacyl
Normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetin guacyl (AMG) 600 mg twice daily
Study: 12573744
Drug: Continuous hyperfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperfractionated accelerated radiotherapy (V-CHART) with mitomycin C (20 mg/m² on day 5)
Study: 8916639
Drug: Psychodynamic‐interpersonal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic‐interpersonal therapy (16 sessions)
Study: 8916639
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (16 sessions)
Study: 8916639
Drug: Psychodynamic‐interpersonal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic‐interpersonal therapy (8 sessions)
Study: 8916639
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (8 sessions)
Study: 8916639
Drug: CPP clients
Normalized name: CPPD
DrugBank: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine (DB14196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP clients (combined treatment approaches)
Study: 8916639
Drug: SPP2 clients
Normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (PIMIENTA CALIENTE) - BROWN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP2 clients (combined treatment approaches)
Study: 30763661
Drug: 18 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 Gy hyperfractionated radiation therapy (RT) given in twice-daily fractions of 1.5 Gy each
Study: 30095381
Drug: Vancomycin (VCM)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin (VCM) 1 g
Study: 30095381
Drug: Ampicillin (AMP)
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin (AMP) 1 g
Study: 22183220
Drug: Porcine subintestinal
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine subintestinal submucosal graft augmentation
Study: 12472197
Drug: Twenty-four hour
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-four hour urinary albumin excretion rates (UAER)
Study: 9531874
Drug: IM triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM triptorelin (3.75 mg)
Study: 9531874
Drug: SC triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC triptorelin (3.75 mg)
Study: 2487529
Drug: Indapamide (IND)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide (IND) 2.5 mg
Study: 2487529
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg (HCTZ + A)
Study: 26989888
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg PEX168
Study: 26989888
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg PEX168
Study: 26296497
Drug: A/H5N2 live
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/H5N2 live attenuated influenza vaccine
Study: 19929597
Drug: ezetimibe/simvastatin (E/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin (E/S) combination therapy
Study: 17016527
Drug: Standardized IOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized IOP treatment protocol (ranging from topical monotherapy to filtration surgery)
Study: 17016527
Drug: Standardized IOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized IOP treatment protocol
Study: 9062507
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (0.15 U/kg)
Study: 9062507
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin (0.15 U/kg)
Study: 9062507
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin (0.1 U/kg)
Study: 9062507
Drug: Ultralente insulin
Normalized name: ultralente insulin, beef
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralente insulin (0.2 U/kg)
Study: 1288510
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 0.2 mg i.v.
Study: 1288510
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 0.5 mg i.v.
Study: 1288510
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 1.0 mg i.v.
Study: 1288510
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 1.5 mg i.v.
Study: 1288510
Drug: n-butylscopolamine bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-butylscopolamine bromide 20 mg i.v.
Study: 30739935
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg/kg
Study: 30739935
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg/kg with Clonidine 1 µg/kg
Study: 29435955
Drug: Neuromuscular manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular manual therapy
Study: 29435955
Drug: Back massage
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back massage therapy
Study: 17713400
Drug: Tight glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glucose control by intensive insulin therapy
Study: 31563122
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate solution
Study: 10470753
Drug: Liposomal prostaglandin
Normalized name: Liposomal prostaglandin E1
DrugBank: Liposomal prostaglandin E1 (DB05391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal prostaglandin E1 (with at least 85% of full dose)
Study: 287554
Drug: Adjuvant high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant high-dose methotrexate and aggressive resection of pulmonary metastases
Study: 30907987
Drug: Levothyroxine 50
Normalized name: LEVOTHYROXINE 50MCG/ML ORAL SOLN UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine 50 μg once daily
Study: 23529786
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral tablet of bilastine
Study: 23529786
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous formulation of bilastine
Study: 14657226
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CTh)
Study: 11136909
Drug: 3000 U
Normalized name: lipase 3000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 U anti-factor Xa certoparin once daily
Study: 11136909
Drug: 3000 U
Normalized name: lipase 3000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 U anti-factor Xa certoparin twice daily
Study: 11136909
Drug: 5000 U
Normalized name: lipase 5000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 U anti-factor Xa certoparin twice daily
Study: 11136909
Drug: 8000 U
Normalized name: lipase 8000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8000 U anti-factor Xa certoparin twice daily
Study: 11136909
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group 4